Itepekimab

依特吉单抗

Report date: 2026/05/28 20:00:21

Base Information

Drug NameItepekimab
Drug Alias NameItepekimabREGN-3500SAR-440340
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-33 inhibitors
TargetsInterleukin-33
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Dermatitis, AtopicNasal Polyps +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[43] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesRegeneron Pharmaceuticals IncSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofiGenzyme Ireland LtdSanofi-Aventis Recherche & Developpement +[5] 
Inactive CompaniesN/A
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Nasal PolypsPulmonary Disease, Chronic Obstructive +[5] 
Inactive IndicationsDermatitis, AtopicAsthma

Other Information

ATC CodeN/A
Related LinksN/A